MSB trading, page-3383

Hey 2 ...if you only get on this site once a week you have time to read this

97%100-Day Survival Rate for Bone Marrow Transplants (2014-2016)

86 Bone Marrow Transplants Performed (in 2016)

Excellent bone marrow outcomes 

Established in 1994, the Center for Cancer and Blood Disorders at Children’s Hospital Colorado offers the region’s only dedicated pediatric bone marrow transplant (BMT) program. We performed more than 80 bone marrow transplants in 2016 for children, teens and young adults with hematologic, oncologic, immunologic and hereditary metabolic conditions.

Children’s Colorado is recognized as meeting the highest standards of 100-day and one-year post-BMT survival compared to other U.S. pediatric BMT programs by the International Bone Marrow Transplant Registry, the NMDP and U.S. News and World Report. See our BMT survival rates.

Established in 1994, the Center for Cancer and Blood Disorders at Children’s Hospital Colorado offers the region’s only dedicated pediatric bone marrow transplant (BMT) program. We performed more than 80 bone marrow transplants in 2016 for children, teens and young adults with hematologic, oncologic, immunologic and hereditary metabolic conditions.

• We offer interventional clinical trials and research studies available only at limited institutions around the world. We also have a partnership with the North American Pediatric. We offer interventional clinical trials and research studies available only at limited institutions around the world. 

• Interesting that 23 specialist researchers from different  centres in the US were involved in analysis of these trials. Did I not read somewhere that MSB could penetrate 50% of the market in the US by marketing to 30 facilities in the US? Looks like good progress to me…..but don’t let the facts get in the way of a falling share price . See below for list of participating hospitals with their specialist researchers.

https://www.childrenscolorado.org/doctors-and-departments/departments/cancer-and-blood-disorders/programs/bone-marrow-transplant/

Just to put things in other perspective for certain posters . The above test results are facts shown on the hospitals own website  . Cynata may have trouble enlisting patients for the clinical trials going forward when survival rates are 97% … but maybe I have got something wrong ?

How did they achieve such amazing results, which are saving so many young lives  ?  I decided to look again at MSB phase 3 results and Cynata phase 1 results and I noticed a rather interesting variation in the cohort groups. You can see from the link below for MSBs clinical trial that 89% of the 55 patients had grade C (iii) or D(IV) aGVHD which is the most severe with a 90% mortality rate . Obviously that infers  that only 11%, or 6 patients were grade B (ii).  This appears to contrast with Cynata who had only 9 out of 15 patients with the more severe designation 3 (C)... with no grade 4(IV)  patients at all ! Interestingly only 5 out of the 9 patients in the C (iii) group had a complete response. These were patients A4,A7,A8,B2 and B3.

MSB results link for MSC-100-IV for steroid refractory aGVHD trials

d8c48d14-a0e1-4364-9c45-8e5aefa85428.png 

Now look at (Page 17) of Cynata's latest presentation for their results

http://files.cynata.com/390/18.11.01.Cynata-Outlook-and-Investor-Presentation.pdf

Obviously I believe there is a major difference in mortality when treating patients in grade III &  IV vs grade II 

FYI ~I found a breakdown grading spectrum as follows: 

This does not take away from Cynata’s excellent results . It is not their fault if they could not enlist a totally representative group for their cohort study  ...but it does appear that MSB  results were based on a cohort group of much sicker patients?……someone please correct me if I have this wrong ? If I am right ,we might be comparing very sick apples with extremely sick pears. I am not sure Fuji will be amused ….but then again I don’t think the Japanese will care to lose face having already spent a fortune trying to get into this area of medicine.

I must stress that I need to present my observations to Mesoblast and Cynata to get their feedback. It is dangerous, with no professional experience of evaluating clinical trial results ,for me to jump to conclusions, but on the basis of what I see ...I think comparisons are not fair or accurate . Please do not rely on my interpretation when making a decision to trades in the securities of either Company. DYOR.

Maybe certain posters on the CYN thread want to phone Amy Keating at the Colorado Hospital and find out…or one of the other 22 specialists around the US

https://www.centerwatch.com/clinical-trials/listings/68909/grades-b-d-agvhd-prospective-study-remestemcel-l-/   

    A Prospective Study of Remestemcel-L Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Brief description of study

The study plans to treat at least 60 paediatric subjects, male and female, between the ages of 2 months and 17 years inclusive with acute Graft versus Host Disease (aGVHD) following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to respond to treatment with systemic corticosteroid therapy. Subjects may have Grades C and D aGVHD involving the skin, liver and/or gastrointestinal (GI) tract or Grade B aGVHD involving the liver and/or GI tract, with or without concomitant skin disease.

Detailed Study Description

Remestemcel-L will be evaluated in pediatric subjects with acute Graft versus Host Disease (aGVHD) following allogeneic hematopoietic stem cell transplant (HSCT) that has failed to respond to treatment with systemic corticosteroid therapy.

Clinical Study Identifier: NCT02336230

Contact Investigators or Research Sites near you 

Alicia McFarren, MD

Children's Hospital Los Angeles

Los Angeles, CA United States

Steven Neudorf, MD

Children's Hospital of Orange County

Orange, CA United States

Ying Lu

University of California at San Francisco

San Francisco, CA United States

Amy Keating, MD

Children's Hospital Colorado Center for Cancer/Blood Disorders

Aurora, CO United States

Emi Caywood, MD

Alfred I. DuPont Hospital for Children of the Nemours Foundation

Wilmington, DE United States

Michael Joyce, MD

Nemours Children's Specialty Care

Jacksonville, FL United States

Sonali Chaudhury, MD

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, IL United States

Lolie Yu, MD

Children's Hospital of New Orleans

New Orleans, LA United States

Jason Law, MD

Tufts Medical Center

Boston, MA United States

Gail Megason, MD

University of Mississippi Medical Center

Jackson, MS United States

Gary Myers, MD

Children's Mercy Hospital

Kansas City, MO United States

Joel Brochstein, MD

Cohen Children's Medical Center of NY

New Hyde Park, NY United States

Prakash Satwani, MD

Columbia University Medical Center

New York, NY United States

Susan Prockop, MD

Memorial Sloan Kettering Cancer Center

New York, NY United States

Kris Mahadeo, MD

Albert Einstein College of Medicine

New York, NY United States

Joanne Kurtzberg, MD

Duke University Medical Center

Durham, NC United States

Eneida Nemecek, MD

Oregon University

Portland, OR United States

Michelle Hudspeth, MD

Medical University of South Carolina

Charleston, SC United States

Victor Aquino, MD

University of Texas Southwestern Medical Center

Dallas, TX United States

Troy Quigg, MD

Texas Transplant Institute

San Antonio, TX United States

Christina Wiedl, MD   

 Virginia Commonwealth University

 Richmond, VA United States

Julie Talano, MD

Medical College of Wisconsin

Milwaukee, WI United States

Shalini Shenoy, MD

Washington University

Saint Louis, MO United States

Recruitment Status: Closed